April 22nd 2025
The findings suggest that women who experience early menopause (age <40 vs >50 years) may constitute a sex-specific high-risk group for cognitive decline.
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Carolina Neuromuscular Disease Summit
September 27, 2025
Register Now!
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials
View More
Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors
View More
Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts
View More
Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis
View More
Identifying and Treating CIDP in the Modern Era
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy
View More
Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease
View More
A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
View More
Lesson No. 1 for Physicians: The Customer Is Always Right
April 30th 2013My first patient had so many things wrong; he left before I could examine his heart and lungs, ask about chest pain, or reconcile his medication list. After his visit, veteran clinic staff noted they hadn’t seen Jim for years and were surprised he had come in at all. I felt the totality of my medical education had been squandered. They kindly reminded me it had just begun.
Top 10 Common Medication Errors-Drug #8: Carbamazepine
April 29th 2013A 9-kg 15-month-old girl with new-onset generalized tonic-clonic seizure was discharged with instructions to take carbamazepine suspension (45 mg PO BID [10 mg/kg/d]), which she'd been receiving in the hospital. In the clinic, her carbamazepine blood level was subtherapeutic. The dose was increased to 68 mg PO BID. A week later, the carbamazepine level was still subtherapeutic, but no doses had been missed. What’s the problem here?
Total Sodium in the Brain Increases Dramatically in Advanced Relapse-Remitting Multiple Sclerosis
January 8th 2013Sodium levels are known to be elevated inside the brain stem, cerebellum, and temporal poles early in the course of MS. This study showed total sodium concentrations to be significantly increased in advanced disease-particularly in normal-appearing brain tissues, concomitant with disability.